{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:24:37Z","timestamp":1778883877195,"version":"3.51.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The discovery of genomic abnormalities present in monoclonal plasma cells has diagnostic, prognostic, and disease-monitoring implications in plasma cell neoplasms (PCNs). However, technical and disease-related limitations hamper the detection of these abnormalities using cytogenetic analysis or fluorescence in situ hybridization (FISH). In this study, 28 bone marrow specimens with known PCNs were examined for the presence of genomic abnormalities using microarray analysis after plasma cell enrichment. Cytogenetic analysis was performed on 15 of 28 samples, revealing disease-related genomic aberrations in only 3 (20%) of 15 cases. FISH analysis was performed on enriched plasma cells and detected aberrations in 84.6% of specimens while array comparative genomic hybridization (aCGH) detected abnormalities in 89.3% of cases. Furthermore, aCGH revealed additional abnormalities in 24 cases compared with FISH alone. We conclude that aCGH after plasma cell enrichment, in combination with FISH, is a valuable approach for routine clinical use in achieving a more complete genetic characterization of patients with PCN.<\/jats:p>","DOI":"10.1309\/ajcpkw31baimvgst","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T23:58:50Z","timestamp":1348531130000},"page":"579-589","source":"Crossref","is-referenced-by-count":15,"title":["Array-Based Karyotyping in Plasma Cell Neoplasia After Plasma Cell Enrichment Increases Detection of Genomic Aberrations"],"prefix":"10.1093","volume":"138","author":[{"given":"Barbara K.","family":"Zehentner","sequence":"first","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luise","family":"Hartmann","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine F.","family":"Stephenson","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas B.","family":"Chapman","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica E.","family":"de Baca","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise A.","family":"Wells","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Loken","sequence":"additional","affiliation":[{"name":"1Hematologics Inc, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Budi","family":"Tirtorahardjo","sequence":"additional","affiliation":[{"name":"2Combimatrix Diagnostics, Irvine, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly R.","family":"Gunn","sequence":"additional","affiliation":[{"name":"2Combimatrix Diagnostics, Irvine, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lony","family":"Lim","sequence":"additional","affiliation":[{"name":"2Combimatrix Diagnostics, Irvine, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,10,1]]},"reference":[{"key":"2023012004411944900_b1-ajcpkw31baimvgst","article-title":"Plasma cell neoplasm","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"McKenna","year":"2008"},{"key":"2023012004411944900_b2-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0268-960X(10)70003-5","article-title":"Multiple myeloma: biology of the disease","volume":"24","author":"Mahindra","year":"2010","journal-title":"Blood Rev."},{"key":"2023012004411944900_b3-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer Statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"2023012004411944900_b4-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajh.22237","article-title":"Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management","volume":"87","author":"Rajkumar","year":"2012","journal-title":"Am J Hematol."},{"key":"2023012004411944900_b5-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinic-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"2023012004411944900_b6-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"2023012004411944900_b7-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"2023012004411944900_b8-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"2023012004411944900_b9-ajcpkw31baimvgst","first-page":"357","article-title":"The use of genetics markers and signatures in multiple myeloma risk stratification","volume-title":"ASCO Educational Book 2011","author":"Fonseca","year":"2011"},{"key":"2023012004411944900_b10-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4149\/neo_2010_02_111","article-title":"Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation","volume":"57","author":"Greslikova","year":"2010","journal-title":"Neoplasma"},{"key":"2023012004411944900_b11-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cancergencyto.2008.11.007","article-title":"Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment","volume":"189","author":"Pozdnyakova","year":"2009","journal-title":"Cancer Genet Cytogenet."},{"key":"2023012004411944900_b12-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002770000245","article-title":"Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement","volume":"80","author":"Draube","year":"2001","journal-title":"Ann Hematol."},{"key":"2023012004411944900_b13-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1309\/AJCPF7NFLW8UAJEP","article-title":"Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques","volume":"136","author":"Hartmann","year":"2011","journal-title":"Am J Clin Pathol."},{"key":"2023012004411944900_b14-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2141.2009.07757.x","article-title":"Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies","volume":"146","author":"Maciejewski","year":"2009","journal-title":"Br J Haematol."},{"key":"2023012004411944900_b15-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"2023012004411944900_b16-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2353\/jmoldx.2009.080101","article-title":"Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using Excel functions","volume":"11","author":"Ciolino","year":"2009","journal-title":"J Mol Diagn."},{"key":"2023012004411944900_b17-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"2023012004411944900_b18-ajcpkw31baimvgst","first-page":"3366","article-title":"Prognostic value of cytogenetics in multiple myeloma","volume":"91","author":"Seong","year":"1998","journal-title":"Br J Haematol."},{"key":"2023012004411944900_b19-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining chromosomal aberrations t(4;14) and del(17p13) with ISS allows a stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"key":"2023012004411944900_b20-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol."},{"key":"2023012004411944900_b21-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2010.21","article-title":"Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma","volume":"24","author":"Chng","year":"2010","journal-title":"Leukemia"},{"key":"2023012004411944900_b22-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","article-title":"Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma","volume":"110","author":"Jenner","year":"2007","journal-title":"Blood"},{"key":"2023012004411944900_b23-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1200\/JCO.2010.31.0516","article-title":"Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma","volume":"29","author":"Tapper","year":"2011","journal-title":"J Clin Oncol."},{"key":"2023012004411944900_b24-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood-2011-03-344069","article-title":"Chromothripsis identifies a rare and aggressive entity among newly diagnosed myeloma patients","volume":"118","author":"Magrangeas","year":"2011","journal-title":"Blood"},{"key":"2023012004411944900_b25-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"2023012004411944900_b26-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","article-title":"The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells","volume":"100","author":"Jourdan","year":"1998","journal-title":"Br J Haematol"},{"key":"2023012004411944900_b27-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12185-011-0948-y","article-title":"The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma","volume":"94","author":"Johnson","year":"2011","journal-title":"Int J Hematol."},{"key":"2023012004411944900_b28-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2007.06586.x","article-title":"Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics","volume":"137","author":"Shaughnessy","year":"2007","journal-title":"Br J Haematol."},{"key":"2023012004411944900_b29-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/leu.2009.160","article-title":"The molecular characterization and clinical management of multiple myeloma in the post-genome era","volume":"23","author":"Zhou","year":"2009","journal-title":"Leukemia"},{"key":"2023012004411944900_b30-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol."},{"key":"2023012004411944900_b31-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2023012004411944900_b32-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"2023012004411944900_b33-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-03-211953","article-title":"Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols","volume":"114","author":"Hoering","year":"2009","journal-title":"Blood"},{"key":"2023012004411944900_b34-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2023012004411944900_b35-ajcpkw31baimvgst","first-page":"629","article-title":"Prediction of cytogenetic abnormalities in multiple myeloma based on gene expression profiles","volume":"118","author":"Zhou","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2023012004411944900_b36-ajcpkw31baimvgst","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin Cancer Res."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/138\/4\/579\/48790819\/ajcp_138_4_579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/138\/4\/579\/48790819\/ajcp_138_4_579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T04:42:00Z","timestamp":1674189720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/138\/4\/579\/1761104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,10,1]]},"published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpkw31baimvgst","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,10,1]]},"published":{"date-parts":[[2012,10,1]]}}}